PFIZER AND THE CHALLENGES OF THE PHARMACEUTICAL INDUSTRY
Analysts have noted that the share prices of firms in the Branded Pharma industry have done quite poorly relative to the US Stock Market as a whole. For instance , over the period 2000-2018, an Index of leading pharmaceutical firms has returned 40% cumulatively, while the S&P 500 has returned over 100%.
READ ATTACHED CASE STUDY
As a senior executive in Pfizer, a large pharma company, you are trying to understand the causes of this underperformance of the industry as well as come up with some strategies to address the problems identified. In general, a systematic approach to understand a change in industry value is to understand the industry structure as it stood at an earlier point in time and then identify and understand the implications of any important trends that have emerged in or impacted the industry. Three common reasons for industry profit potential to decline are a) a decline in the industrys value creation, b) an increase in the vertical competition threats faced by the industry, c) an increase in the overall horizontal competition in the industry. Understanding each of these three possibilities by identifying which drivers in each of the three cases above have worsened can also help in developing a set of strategies that systematically address the sources of industry decline. With this thought process in mind please answer the following questions
(1)Has the branded pharmaceutical industrys value creation declined? If so, which drivers do you see as causing this decline? Support your answer by identifying and explaining the drivers you see as responsible for the decline.
(2)Have the vertical competition threats facing the industry worsened? Support your answer by identifying and explaining the vertical threats facing the industry
(3)Has the horizontal competition in the industry worsened Support your answer by identifying and explaining the horizontal competition threats facing the industry
(4)What would you recommend that an industry leader such as Pfizer should do to counter the threats you have identified. A detailed strategy is not required here. Just a listing of the the strategic responses you would recommend the management consider with justification of each recommended strategic response will suffice.